The DIAMOND RCT [15] showed that, compared with SMBG, rtCGM resulted in a greater HbA1c reduction (MD −0.3 pp [–3 mmol/mol]) in a type 2 diabetes population treated with multiple daily insulin injections (MDI). The gene discussed is INS; the disease is type 2 diabetes mellitus.